Moderna Reports ‘Robust’ Response From COVID-19 Booster Shots
Pipeline Sees Continued Progress, Helped By Vaccine Windfall
Executives said the company was “capacity constrained” for 2021 and not taking further mRNA-1273 vaccine orders for delivery this year.
You may also be interested in...
The company anticipates another year of big sales for its COVID-19 vaccine, but is also touting a pipeline of 44 programs in development, with oncology and possibly rare disease data this year.
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.
The FDA granted an expected, though long-awaited, approval to the COVID-19 vaccine. Also, Korean regulators have begun a review of Russian vaccine CoviVac, while Bavarian Nordic has initiated a Phase II study of its vaccine booster candidate and received a commitment for up to DKK 800m from the Danish government.